Business
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a
About this update from Newamsterdam Pharma Company N.v.
[{"type":"text","content":"NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the commercialization of multiple blockbuster medicines including LIPITOR® and CRESTOR®. “We are delighted to welcome Adele to our Board of Directors at a critical juncture for NewAmsterdam, as we prepare for the potential launch of obicetrapib next year,” said Michael Davidson, M.D., Ph.D., Chief Executive Officer of NewAmsterdam Pharma. “Adele brings world-class commercial leadership and an exceptional track record of successfully launching blockbuster therapies on a global scale. Her strategic insight, mass-market drug launch experience and deep operational expertise will be instrumental as we work diligently to finalize our commercial strategy and build the infrastructure to support our first commercial launch, if approved.” Most recently, Ms. Gulfo served as Chief Executive Officer for the Biopharma Commercial Unit at Sumitomo Pharma America, Inc., where she oversaw the commercial and development portfolio across various therapeutic areas, including oncology, rare disease, diabetes, urology, neurology, and women's health. Prior to Sumitomo, she was the Chief Commercial and Business Development Officer at Sumitovant Biopharma until its integration into Sumitomo Pharma America. Before joining Sumitovant, Ms. Gulfo served as Chief Commercial Development Officer at Roivant Sciences, where she played a key role in the formation of Sumitovant and led launch preparations for several major brands, such as ORGOVYX®, GEMTESA®, RETHYMIC®, and MYFEMBREE®. Earlier, Ms. Gulfo was the President and General Manager of Pfizer's U.S. primary care business unit, which generated over $12 billion in revenue. At Pfizer, she was ...